Sensex (File | Reuters) 
Business

Aurobindo Pharma jumps over 8 per cent on FDA nod

The scrip of the drug firm surged 8.27 per cent to Rs 794.50 on BSE. At NSE, shares of the company jumped 8.22 per cent to Rs 794.70.

From our online archive

NEW DELHI: Shares of Aurobindo Pharma soared over 8 per cent today after the company received final approval from the USFDA to manufacture and market Sevelamer Carbonate tablets.     

The scrip of the drug firm surged 8.27 per cent to Rs 794.50 on BSE.     

At NSE, shares of the company jumped 8.22 per cent to Rs 794.70.     

In terms of volume, 4.63 lakh shares of the company were traded on BSE and over 81 lakh shares changed hands at NSE during morning trading session.     

The tablets are indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.     

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobindo Pharma said in a BSE filing today.

The real AI story of 2026 will be found in the boring, the mundane—and in China

Migration and mobility: Indians abroad grapple with being both necessary and disposable

Days after Bangladesh police's Meghalaya charge, Osman Hadi's alleged killer claims he is in Dubai

Post Operation Sindoor, Pakistan waging proxy war, has clear agenda to destabilise Punjab: DGP Yadav

Gig workers declare protest a success, say three lakh across India took part

SCROLL FOR NEXT